JP2021501159A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501159A5 JP2021501159A5 JP2020523705A JP2020523705A JP2021501159A5 JP 2021501159 A5 JP2021501159 A5 JP 2021501159A5 JP 2020523705 A JP2020523705 A JP 2020523705A JP 2020523705 A JP2020523705 A JP 2020523705A JP 2021501159 A5 JP2021501159 A5 JP 2021501159A5
- Authority
- JP
- Japan
- Prior art keywords
- individual
- composition according
- c5ar
- antagonist
- scd163
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023112051A JP2023133317A (ja) | 2017-10-31 | 2023-07-07 | Ｃ５ａＲ阻害剤による尿中ｓＣＤ１６３の減少 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579716P | 2017-10-31 | 2017-10-31 | |
| US62/579,716 | 2017-10-31 | ||
| PCT/US2018/058134 WO2019089534A1 (en) | 2017-10-31 | 2018-10-30 | C5aR INHIBITOR REDUCTION OF URINARY sCD163 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023112051A Division JP2023133317A (ja) | 2017-10-31 | 2023-07-07 | Ｃ５ａＲ阻害剤による尿中ｓＣＤ１６３の減少 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501159A JP2021501159A (ja) | 2021-01-14 |
| JP2021501159A5 true JP2021501159A5 (https=) | 2021-12-09 |
| JP7789483B2 JP7789483B2 (ja) | 2025-12-22 |
Family
ID=66326509
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523705A Active JP7789483B2 (ja) | 2017-10-31 | 2018-10-30 | Ｃ５ａＲ阻害剤による尿中ｓＣＤ１６３の減少 |
| JP2023112051A Pending JP2023133317A (ja) | 2017-10-31 | 2023-07-07 | Ｃ５ａＲ阻害剤による尿中ｓＣＤ１６３の減少 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023112051A Pending JP2023133317A (ja) | 2017-10-31 | 2023-07-07 | Ｃ５ａＲ阻害剤による尿中ｓＣＤ１６３の減少 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190134020A1 (https=) |
| EP (2) | EP4671767A3 (https=) |
| JP (2) | JP7789483B2 (https=) |
| KR (1) | KR20200109297A (https=) |
| CN (1) | CN111670185A (https=) |
| AR (1) | AR113815A1 (https=) |
| AU (2) | AU2018359237A1 (https=) |
| CA (1) | CA3078732A1 (https=) |
| WO (1) | WO2019089534A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3801519A4 (en) | 2018-06-07 | 2022-03-30 | ChemoCentryx, Inc. | DOSAGE AND EFFECTS OF C5A ANTAGONIST WITH ANCA-ASSOCIATED VASCULITIS |
| SMT202400521T1 (it) | 2018-11-30 | 2025-01-14 | Chemocentryx Inc | Formulazioni di capsula |
| CA3235574A1 (en) * | 2019-11-08 | 2021-05-14 | Chemocentryx, Inc. | Salt forms of a complement component c5a receptor |
| CN114641288A (zh) | 2019-11-08 | 2022-06-17 | 凯莫森特里克斯股份有限公司 | 补体成分C5a受体的无定形形式 |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| WO2022093971A1 (en) * | 2020-10-28 | 2022-05-05 | Chemocentryx, Inc. | Methods of treating hidradenitis suppurativa |
| CN116529241A (zh) * | 2020-10-28 | 2023-08-01 | 坎莫森特里克斯公司 | 治疗化脓性汗腺炎的方法 |
| EP4262800A4 (en) * | 2020-12-21 | 2024-11-20 | ChemoCentryx, Inc. | TREATMENT OF C3 GLOMERULOPATHY WITH A C5A INHIBITOR |
| AU2022207985A1 (en) | 2021-01-13 | 2023-07-06 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1268002A (en) | 1917-09-12 | 1918-05-28 | William M Goodwin | Measuring instrument. |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| CA2965223C (en) | 2008-12-22 | 2019-09-24 | Chemocentryx, Inc. | C5ar antagonists |
| US20110275639A1 (en) * | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| PT2585064T (pt) * | 2010-06-24 | 2017-08-08 | Chemocentryx Inc | Antagonistas do c5ar |
| NZ730123A (en) | 2014-09-29 | 2023-05-26 | Chemocentryx Inc | Processes and intermediates in the preparation of c5ar antagonists |
| WO2016166357A2 (en) * | 2015-04-17 | 2016-10-20 | The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth, Near Dublin | Method and assay for diagnosing rapidly progressive glomerulonephritis in a subject |
| AU2017246228B2 (en) * | 2016-04-04 | 2021-04-15 | Chemocentryx, Inc. | Soluble C5aR antagonists |
-
2018
- 2018-10-30 AU AU2018359237A patent/AU2018359237A1/en not_active Abandoned
- 2018-10-30 EP EP25198900.0A patent/EP4671767A3/en active Pending
- 2018-10-30 US US16/174,658 patent/US20190134020A1/en not_active Abandoned
- 2018-10-30 WO PCT/US2018/058134 patent/WO2019089534A1/en not_active Ceased
- 2018-10-30 CN CN201880070265.5A patent/CN111670185A/zh active Pending
- 2018-10-30 CA CA3078732A patent/CA3078732A1/en active Pending
- 2018-10-30 EP EP18873880.1A patent/EP3704110A4/en not_active Ceased
- 2018-10-30 KR KR1020207015095A patent/KR20200109297A/ko not_active Ceased
- 2018-10-30 JP JP2020523705A patent/JP7789483B2/ja active Active
- 2018-10-31 AR ARP180103168A patent/AR113815A1/es unknown
-
2022
- 2022-07-29 US US17/815,992 patent/US20230105869A1/en active Pending
-
2023
- 2023-07-07 JP JP2023112051A patent/JP2023133317A/ja active Pending
-
2024
- 2024-04-19 AU AU2024202593A patent/AU2024202593A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501159A5 (https=) | ||
| Kramers et al. | Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease | |
| Ling et al. | Anakinra reduces blood pressure and renal fibrosis in one kidney/DOCA/salt-induced hypertension | |
| ES2656897T3 (es) | Procedimientos de predicción del riesgo de desarrollar hipertensión | |
| CN104284665B (zh) | 吡唑衍生物及其医药用途 | |
| JP2012502113A5 (https=) | ||
| RU2012147597A (ru) | Биомаркеры для ингибиторов mdm2, использующиеся для лечения заболевания | |
| JP7814368B2 (ja) | 慢性腎疾患の治療のためのジボテンタン及びダパグリフロジンの組み合わせ | |
| JP2018503618A5 (https=) | ||
| Zhang et al. | Blockage of VEGF function by bevacizumab alleviates early-stage cerebrovascular dysfunction and improves cognitive function in a mouse model of Alzheimer’s disease | |
| JP2017511377A5 (https=) | ||
| CN111936127A (zh) | 炎症性疾病或骨病的预防或治疗剂及医药组合物 | |
| JP2016512201A5 (https=) | ||
| Abbas et al. | The role of serum IL-1β in combination with fractional exhaled nitric oxide in the diagnosis of adult bronchial asthma | |
| Matsuura et al. | Prior exposure to placental ischemia causes increased salt sensitivity of blood pressure via vasopressin production and secretion in postpartum rats | |
| DK2451452T3 (en) | Use of benzydamine in the treatment of p40-dependent diseases | |
| Sincar et al. | The biochemical effects of non-surgical periodontal therapy in patients with and without chronic renal disease | |
| Ohta et al. | Effects of benidipine, a long-acting T-type calcium channel blocker, on home blood pressure and renal function in patients with essential hypertension: a retrospective,‘real-world’comparison with amlodipine | |
| EP2626702A1 (en) | Diagnostic agent, diagnostic method and therapeutic agent for fibromyalgia | |
| US11844792B2 (en) | Treatment for severe acute respiratory illness associated with coronavirus | |
| CN1604777A (zh) | 治疗方法 | |
| Shen et al. | Fluoxetine treatment for major depression decreases the plasma levels of cytokines | |
| WO2022019235A1 (ja) | 腎障害の抑制におけるビタミンｂ１２の利用 | |
| Olivencia Plaza | Vitamin D deficiency and chronic alcohol consumption as predisposing factors of erectile dysfunction and pulmonary hypertension | |
| US20230330083A1 (en) | Compositions and methods for treating or preventing pulmonary hypertension |